In a retrospective study from Canada examining clinical practice patterns of G-CSF use between 2008 and 2019, 57% of 6662 patients receiving NACT or ACT for breast cancer were prescribed G-CSF at some point during treatment. This evidence concerns the gene CSF3 and breast cancer.